Interestingly, the proportion of CD16+ in the CD56− T subset in samples obtained from MS patients was higher compared to the HD group (Figure 4f), which may serve as a compensatory mechanism in response to a decrease in this receptor on NK cells. This evidence concerns the gene FCGR3A and myeloid sarcoma.